Arcellx Inc

Arcellx Inc. (ALEX) gains analyst confidence amid stock volatility and competitive pressure from Kelonia, offering investors a potential entry point in adaptive‑immune oncology.

Arcellx, Inc. is a development-stage pharmaceutical company pioneering adaptive immune cell therapies to combat cancer, despite experiencing market fluctuations and a significant decrease in stock value.